pharma

Showing 15 posts of 2914 posts found.

FDA approves Pfizer’s Ibrance for advanced male breast cancer

April 5, 2019
Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …

astrazeneca-sign

AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome

April 4, 2019
Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma

AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study

April 3, 2019
Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma

Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …

shutterstock_159488225

Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show

April 3, 2019
Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma

At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …

novartis_outside_1

Novartis’ Cosentyx approved in China for plaque psoriasis

April 2, 2019
Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis

Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …

teva_canada_1

Teva’s Ajovy injection secures EU approval for the prevention of migraine

April 2, 2019
Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma

Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …

merckwindow_web

China approves Keytruda for non-small cell lung cancer

April 2, 2019
Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma

US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …

love-and-drugs-1

How I learned to stop worrying and love the placebo effect

April 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, pharma, placebo effect

Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for …

novartis_outside_1

Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics

April 1, 2019
Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma

Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …

roche__tree

Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

April 1, 2019
Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …

shutterstock_273326141

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …

shutterstock_57369385

England’s antidepressant prescriptions double to 70m in a decade

March 29, 2019
Medical Communications England, UK, antidepressants, anxiety, depression, pharma

Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …

eye2

J&J’s antihistamine-releasing contact lens shows promise in Phase 3 trials

March 28, 2019
Research and Development J&J, JJ, eye care, pharma

Johnson and Johnson has unveiled new Phase 3 data on its antihistamine-releasing contact lens, showing that the investigational product led …

The Gateway to Local Adoption Series

Latest content